Drug intelligence / Profile preview

SCLife-LDD

Development stage: Unknown
Lead developer: Sclnow Biotechnology
Modality: Cell Therapies
Administration: Intradiscal

Overview

SCLife-LDD is an investigational biologic therapy consisting of human umbilical cord mesenchymal stem cells (hUC-MSCs) injection developed by Sclnow Biotechnology Co., Ltd. for treating lumbar intervertebral disc degeneration. It leverages the regenerative properties of mesenchymal stem cells, which are believed to modulate inflammation, promote tissue repair, and inhibit disc degeneration through paracrine effects and differentiation potential. The therapy is administered via injection and is currently in suspended early-phase clinical development, with a phase 1/2 trial (NCT05116475 or similar) extended to completion dates in 2025-2026.

Brand names: SCLife-LDD
Other names: SCLife®-LDD hUC-MSCs Injection

Beyond the preview

Go deeper on SCLife-LDD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCLife-LDD.